Advertisement
Canada markets close in 35 minutes
  • S&P/TSX

    22,292.28
    +32.81 (+0.15%)
     
  • S&P 500

    5,186.04
    +5.30 (+0.10%)
     
  • DOW

    38,877.28
    +25.01 (+0.06%)
     
  • CAD/USD

    0.7284
    -0.0037 (-0.51%)
     
  • CRUDE OIL

    78.48
    0.00 (0.00%)
     
  • Bitcoin CAD

    86,654.91
    +118.50 (+0.14%)
     
  • CMC Crypto 200

    1,309.80
    -55.32 (-4.05%)
     
  • GOLD FUTURES

    2,322.90
    -8.30 (-0.36%)
     
  • RUSSELL 2000

    2,069.78
    +9.11 (+0.44%)
     
  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     
  • NASDAQ

    16,336.45
    -12.80 (-0.08%)
     
  • VOLATILITY

    13.31
    -0.18 (-1.33%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6771
    -0.0021 (-0.31%)
     

PENUMBRA INVESTOR ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Penumbra To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE:PEN).

If you suffered losses exceeding $50,000 investing in Penumbra stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/PEN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

There is no cost or obligation to you.

On November 10, 2020, Quintessential Capital Management issued a research report on Penumbra entitled "Penumbra and its ‘Killer Catheter’: A tale of corporate greed and seemingly blatant disregard for patients’ lives[.]"

ADVERTISEMENT

Then, on December 8, 2020, Quintessential Capital Management released a follow-up research report entitled "Is Penumbra’s core scientific research authored by a fake person?: The incredible story of Penumbra’s Dr. Antik Bose[.]" The report alleged that some of the Company’s scientific research appear to have been incorrectly credited or even authored by a fake individual.

On the news of the report, Penumbra’s stock price fell $19.95 per share, or 8.91%, to close at $204.07 per share on December 8, 2020.

Then, on December 15, 2020, after the market, Penumbra announced that it was voluntarily "recalling its JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use[, which] may result in potential vessel damage, and subsequent patient injury or death."

On this news, Penumbra’s stock price fell $13.84 per share, or 7.33%, to a close of $174.98 per share on December 16, 2020.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.